Novel anti-human tie-2 antibody
AssigneeAstellas Pharma Inc.
InventorsMasazumi Kamohara, Shigenori YAGI, Yoshinori ISHll, Hiromi NARA
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstellas Pharma Inc.
InventorsMasazumi Kamohara, Shigenori YAGI, Yoshinori ISHll, Hiromi NARA
Estimating the term…
Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.
A polynucleotide selected from the group consisting of (a) and (b):
A polynucleotide selected from the group consisting of (a) and (b):
An expression vector comprising:
An expression vector comprising;
A host cell selected from the group consisting of (a) to (d) below:
A host cell selected from the group consisting of (a) to (d) below:
A method for producing an anti-human Tie2 antibody or an antigen-binding fragment thereof, comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express a tetravalent anti-human Tie2 antibody or an antigen-binding fragment thereof:
A method for producing an anti-human Tie2 antibody, comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express an anti-human Tie2 antibody:
Dependencies are inferred from the claim text.